ClinicalTrials.gg
CompletedNCT02907060Updated Dec 22, 2025

Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies

A Phase 3 interventional study of Mechanical cervical ripening and Pharmacological cervical ripening in Prolonged Pregnancy, sponsored by University Hospital, Tours. Completed at 14 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by University Hospital, Tours · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,224
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

A pregnancy is considered ''prolonged'' from 41 weeks of gestation. Prolonged Pregnancies (PP) are associated with increased maternal morbidity: emergency caesarean, 3rd and 4th degree perineal lesions and postpartum haemorrhage. Foetuses are at increased risk of oligohydramnios, meconium-staining and Fetal Heart Rate (FHR) anomalies. Around 15% of all pregnancies are prolonged.

A Cochrane review on induction of labour showed that a policy of labour induction at or beyond 41 weeks was associated with significantly fewer perinatal deaths. Thus the French College of Obstetricians and Gynaecologists stated, "induction of labour can be proposed to patients between 41+0 and 41+6 weeks of gestation". In cases where labour is induced and cervix is unfavourable, cervical ripening is advised. Methods of cervical ripening include pharmacological (prostaglandins) and mechanical (Foley catheter or trans-cervical double balloon) methods. Those two methods were compared in the PROBAAT trial among women with term pregnancies (beyond 37+0). The rates of caesarean section with these two strategies were identical, however uterine hyper stimulation with FHR anomalies occurred less when cervical ripening was mechanical.

Considering pharmacological cervical ripening is associated with more uterine hyper stimulation and more FHR anomalies, it may not be the most appropriate in cases of fragile foetuses that include cases of prolonged pregnancies. Considering prolonged pregnancies are associated with a risk of FHR anomalies and that cervical ripening with a pharmacological method is another factor which increases this risk: women with prolonged pregnancies could benefit from a more "gentle" cervical ripening.

At present, no particular method is recommended in cases of cervical ripening and prolonged pregnancies. We hypothesise that, in cases of prolonged pregnancies, mechanical cervical ripening, with less uterine hyperstimulation and fewer FHR anomalies, could be more appropriate and could reduce the rate of caesarean section for suspicion of fetal distress.

02

Conditions studied

  • Prolonged Pregnancy

Browse trials for

Keywords

  • prolonged pregnancy
  • mechanical cervical ripening
03

In context

Pregnancy, Prolonged

30 studies on the registry are indexed under Pregnancy, Prolonged; 3 are open to participants now.

This study's enrollment of 1,224 is above the median of 128 across 24 interventional studies indexed under Pregnancy, Prolonged.

Browse Pregnancy, Prolonged studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women
  • ≥ 18 years old
  • With a singleton cephalic pregnancy between ≥41+0 weeks and ≤ 42+0 weeks of gestation
  • Gestational age estimated from the first trimester ultrasound (realized between 11 and 13+6 weeks of gestation)
  • With a decision of induction of labour
  • Written obtained from subject
  • Subject covered by or having the rights to the French Social Security system

Exclusion criteria

Exclusion Criteria:

  • Bishop score ≥ 6 (favourable cervix)
  • Non cephalic presentation (breech, transverse)
  • Severe preeclampsia defined as the presence of preeclampsia with at least one of the following items :

    • Severe maternal hypertension (systolic blood pressure ≥ 160 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg)
    • Renal failure with oliguria (\< 500 ml/24h) or creatinine > 135μmol/L, or proteinuria > 5 g/day
    • Pulmonary oedema, epigastric pain or HELLP syndrom (hemolysis, elevated liver enzyme, low )
    • Eclampsia or neurologic persisting symptoms (visual disturbances, headache, increased reflexes)
    • Thrombopenia \< 100 G/L
  • Prior caesarean section or uterine scar
  • Placenta praevia
  • Suspected genital herpes infection
  • Known VIH seropositivity (confirmed by blood serology)
  • Premature rupture of membranes (PROM - continual leaking of amniotic fluid or positive test in favour of PROM)
  • Foetus with suspected severe congenital abnormalities
  • Pathological fetal heart rate
  • to Propess®
  • Contra-indications for using Cook® Cervical Ripening Balloon
  • Women under guardianship or trusteeship
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,224 participants (actual)

Study arms

  • Experimental
    Mechanical cervical ripening

    mechanical cervical ripening with a Cook® Cervical Ripening Balloon

    Device: Mechanical cervical ripening

  • Active comparator
    Pharmacological cervical ripening

    pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)

    Drug: Pharmacological cervical ripening

Interventions

  • DeviceMechanical cervical ripening

    The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon. It will be used in accordance with user manual

  • DrugPharmacological cervical ripening

    The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2). It will be used in accordance with Summary of Product Characteristics

06

What researchers measure

Primary outcomes

  1. Caesarean section rate for non-reassuring fetal status.

    Indication of the caesarean section will be settled by an adjudication committee at the end of the study

    Time frame: Up to 2 days after cervical ripening

Secondary outcomes

  1. Time between cervical ripening and delivery in hours

    Evaluation of time between cervical ripening and delivery in hours

    Time frame: Up to 2 days after cervical ripening

  2. Delivery rate after 12 and 24 hours of cervical ripening

    Evaluation of delivery rate after 12 and 24 hours of cervical ripening

    Time frame: up to 2 days after cervical ripening

  3. Induction with oxytocin

    yes/no

    Time frame: up to 2 days after cervical ripening

  4. Total dose of oxytocin required for induction of labour

    evaluation of total dose of oxytocin required for induction of labour

    Time frame: up to 2 days after cervical ripening

  5. Uterine hyper stimulation defined as more than 6 contractions by 10 minutes over a 30 minutes period

    uterine hyperstimulation

    Time frame: up to 2 days after cervical ripening

  6. Requirement for tocolysis during cervical ripening or during labour

    requirement for tocolysis

    Time frame: up to 2 days after cervical ripening

  7. Suspicious or pathological fetal heart rate

    FIGO classification

    Time frame: up to 2 days after cervical ripening

  8. Uterine rupture

    yes/no

    Time frame: up to 2 days after cervical ripening

  9. Use of analgesics during labour

    yes/no

    Time frame: up to 2 days after cervical ripening

  10. Use of antibiotics during labour

    yes/no

    Time frame: up to 2 days after cervical ripening

  11. Indication for caesarean delivery other than non-reassuring FHR

    (failure to progress in first or second stage of labour or maternal indication)

    Time frame: up to 2 days after cervical ripening

  12. Type of vaginal delivery

    spontaneous or instrumental, indication for instrumental delivery

    Time frame: up to 2 days after cervical ripening

  13. Maternal intra partum infection

    Suspicion of maternal intra partum infection

    Time frame: up to 2 days after cervical ripening

  14. Maternal post partum infection

    Suspicion of post partum infection

    Time frame: up to 2 days after cervical ripening

  15. Maternal post partum haemorrhage

    Post partum haemorrhage defined as estimated blood loss \> 500 cc

    Time frame: up to 2 days after cervical ripening

  16. Maternal blood transfusion

    Blood transfusion

    Time frame: up to 2 days after cervical ripening

  17. Neonatal apgar score

    Apgar score at 1, 3, 5 and 10 minutes

    Time frame: at 1, 3, 5 and 10 minutes after delivery

  18. Neonatal arterial ph

    Arterial pH at delivery

    Time frame: at delivery

  19. Intensive care unit for newborn

    Admission in an intensive care unit

    Time frame: up to 5 days after cervical ripening

  20. Neonatal respiratory insufficiency

    Respiratory insufficiency with necessity of any respiratory support

    Time frame: up to 5 days after cervical ripening

  21. Birth asphyxia

    Birth asphyxia defined as pH\<7, Base Excess \>12 mmol/l and encephalopathy.

    Time frame: up to 5 days after cervical ripening

07

Study locations

14 sites
  • Chu Brest
    Brest, France
  • CHU CAEN
    Caen, 14033, France
  • Ch Pontoise
    Cergy-Pontoise, 95303, France
  • Ch Chartres
    Chartres, France
  • Chu Clermont-Ferrand
    Clermont-Ferrand, 63001, France
  • Ch Departemental Vendee
    La Roche-sur-Yon, 85925, France
  • Hopital Saint Joseph
    Marseille, 13008, France
  • Chu Nantes
    Nantes, 44093, France
  • Chi Poissy
    Poissy, France
  • Chu Reims
    Reims, 51092, France
  • Chu Rennes
    Rennes, France
  • Chu Saint Etienne
    Saint-Priest-en-Jarez, 42270, France
  • Chu Toulouse
    Toulouse, France
  • Chru Tours
    Tours, 37044, France
08

References and documents

Publications

  • Diguisto C, Le Gouge A, Arthuis C, Winer N, Parant O, Poncelet C, Chauleur C, Hannigsberg J, Ducarme G, Gallot D, Gabriel R, Desbriere R, Beucher G, Faraguet C, Isly H, Rozenberg P, Giraudeau B, Perrotin F; Groupe de Recherche en Obstetrique et Gynecologie (GROG). Cervical ripening in prolonged pregnancies by silicone double balloon catheter versus vaginal dinoprostone slow release system: The MAGPOP randomised controlled trial. PLoS Med. 2021 Feb 11;18(2):e1003448. doi: 10.1371/journal.pmed.1003448. eCollection 2021 Feb. PubMed 33571294 ↗
  • de Vaan MD, Ten Eikelder ML, Jozwiak M, Palmer KR, Davies-Tuck M, Bloemenkamp KW, Mol BWJ, Boulvain M. Mechanical methods for induction of labour. Cochrane Database Syst Rev. 2023 Mar 30;3(3):CD001233. doi: 10.1002/14651858.CD001233.pub4. PubMed 36996264 ↗
  • Diguisto C, Le Gouge A, Giraudeau B, Perrotin F. Mechanical cervicAl ripeninG for women with PrOlongedPregnancies (MAGPOP): protocol for a randomised controlled trial of a silicone double balloon catheter versus the Propess system for the slow release of dinoprostone for cervical ripening of prolonged pregnancies. BMJ Open. 2017 Sep 14;7(9):e016069. doi: 10.1136/bmjopen-2017-016069. PubMed 28912192 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Dec 2018, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2016
First posted
Sep 20, 2016
StartActual
Jan 27, 2017
Primary completionActual
Dec 12, 2018
CompletionActual
Dec 12, 2018
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02907060
Responsible party
Sponsor
First posted
Sep 20, 2016
Start date
Jan 27, 2017
Primary completion
Dec 12, 2018
Completion
Dec 12, 2018
Last update
Dec 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion